TECHNEGAS KIT Drug Patent Profile

Which patents cover Technegas Kit, and when can generic versions of Technegas Kit launch?

Technegas Kit is a drug marketed by Cyclomedica and is included in one NDA. There is one patent protecting this drug.

This drug has fourteen patent family members in ten countries.

The generic ingredient in TECHNEGAS KIT is technetium tc-99m labeled carbon. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the technetium tc-99m labeled carbon profile page.

DrugPatentWatch^® Generic Entry Outlook for Technegas Kit

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 29, 2026. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TECHNEGAS KIT

International Patents:	14
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	2
DailyMed Link:	TECHNEGAS KIT at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TECHNEGAS KIT

Constraining patent/regulatory exclusivity:

NEW PRODUCT

NDA:

022335

Dosage:

AEROSOL;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TECHNEGAS KIT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cyclomedica Australia PTY Limited	Phase 3

See all TECHNEGAS KIT clinical trials

US Patents and Regulatory Information for TECHNEGAS KIT

TECHNEGAS KIT is protected by one US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW PRODUCT.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cyclomedica	TECHNEGAS KIT	technetium tc-99m labeled carbon	AEROSOL;INHALATION	022335-001	Sep 29, 2023		RX	Yes	Yes
Cyclomedica	TECHNEGAS KIT	technetium tc-99m labeled carbon	AEROSOL;INHALATION	022335-001	Sep 29, 2023		RX	Yes	Yes

International Patents for TECHNEGAS KIT

See the table below for patents covering TECHNEGAS KIT around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2006200755	Improved process for the production of a radioactive aerosol
Australia	2011202136	Improved process for the production of a radioactive aerosol
Canada	2538192	PROCEDE AMELIORE POUR LA PRODUCTION D'UN AEROSOL RADIOACTIF (IMPROVED PROCESS FOR THE PRODUCTION OF A RADIOACTIVE AEROSOL)
China	101217983	Improved process for the production of a radioactive aerosol
Denmark	1745803
European Patent Office	1745803	Procédé amélioré pour la production d'un aérosol radioactif (Improved process for the production of a radioactive aerosol)

Supplementary Protection Certificates for TECHNEGAS KIT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1178838	300736	Netherlands		PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119

Last updated: June 5, 2026

TECHNEGAS KIT market dynamics and financial trajectory: supply, reimbursement, pricing, and exclusivity drivers

TECHNEGAS KIT is a diagnostic technetium Tc 99m generator product used for ventilation imaging in nuclear medicine. Market dynamics are shaped by (1) hospital imaging volume and substitution between ventilation/perfusion workflows, (2) equipment and protocol standardization at imaging centers, (3) reimbursement rates for V/Q imaging and related nuclear medicine professional components, and (4) supply continuity for Tc-99m generator logistics. Financial trajectory hinges on utilization growth tied to cardiopulmonary diagnostic demand, offset by competitive and modality substitution pressures (CT pulmonary angiography and MR workflows), and by the near-term value at risk from any generator supply constraints or label-limiting safety/usage constraints.

No complete, decision-grade financial dataset (revenue by product, net sales, channel share, wholesale acquisition cost history, payer mix, or FDA/NDC-level utilization) is present in the prompt, so a full financial trajectory with quantified baselines and forecast bands cannot be produced without fabricating figures.

---

What market dynamics drive TECHNEGAS KIT demand in nuclear medicine?

Featured-snippet answer: Demand tracks closely to hospital nuclear medicine ventilation-perfusion (V/Q) usage, institutional imaging protocols, and Tc-99m generator supply stability, with substitution from CTPA limiting upside in some settings.

Key demand drivers

• V/Q imaging utilization and case mix

  • TECHNEGAS KIT is positioned for pulmonary ventilation imaging used in V/Q strategies for suspected pulmonary embolism (PE) and other ventilation-pathology workflows.
  • Volume is constrained by ordering practices tied to clinical guidelines and payer coverage rules for V/Q versus CT angiography.

• Institutional protocol standardization

  • Imaging centers often standardize on a small number of ventilation agents and imaging pathways based on department experience, scanner availability, technologist workflow, and reading turnaround time.

• Tc-99m generator availability and logistics

  • TECHNEGAS KIT depends on Tc-99m availability through generator supply networks. Market behavior during Tc-99m shortages can include substitution, deferrals, or changes in protocol choice.

• Reimbursement economics

  • Uptake depends on total reimbursement for imaging episodes, including:
    • facility fee
    • professional interpretation
    • nuclear medicine technical and professional components
  • Shifts in reimbursement relative to CTPA can tilt adoption.

Key headwinds

• Modality substitution

  • CT pulmonary angiography (CTPA) can substitute for V/Q imaging, particularly when CT capacity and clinical pathways support CTPA-first strategies.
  • Any regional differences in CT adoption affect TECHNEGAS KIT utilization.

• Utilization and safety-driven protocol constraints

  • Any restrictions impacting eligible patient populations or required handling/administration steps affect throughput and reorder rates.

• Tender and contracting dynamics

  • Many hospital systems procure imaging products through group purchasing organizations or national contracts. Price pressure and substitute agent availability can reduce unit economics.

---

How do competitors and imaging alternatives affect TECHNEGAS KIT pricing power?

Featured-snippet answer: Pricing power is typically limited by competitive procurement cycles and substitution to other ventilation imaging approaches and non-V/Q pathways.

Competitive substitution set

TECHNEGAS KIT’s practical competition is not “another brand in the same vial,” but alternative pathways:

• Ventilation alternatives within nuclear medicine workflows (other ventilation imaging approaches)
• CTPA-first diagnostic strategies for suspected PE
• Hybrid pathways that triage patients by pre-test probability and imaging access

Impact on commercial leverage

• If institutions can achieve diagnostic endpoints with alternatives at similar or better reimbursement, TECHNEGAS KIT’s negotiating position weakens.
• When V/Q imaging is required by protocol or by patient selection rules, market share becomes more path-dependent and less susceptible to pure price competition.

---

What does the supply chain and Tc-99m generator market imply for TECHNEGAS KIT financial stability?

Featured-snippet answer: Financial trajectory is sensitive to Tc-99m generator supply reliability, distributor inventory behavior, and hospital scheduling continuity.

Supply chain mechanics

• TECHNEGAS KIT relies on generator-derived Tc-99m activity. Producer and distributor behavior affects:
  • order fill rates
  • lead times
  • expiring inventory waste risk
  • emergency allocation practices during shortage periods

Shortage-period dynamics

During Tc-99m scarcity events, the market often sees:

• rationing and priority fulfillment
• shifts toward sites with reliable generator logistics
• temporary changes in imaging mix and utilization deferrals

These effects can temporarily distort revenue timing without improving long-term demand.

---

When do exclusivity, patent life, and regulatory status impact TECHNEGAS KIT revenue?

Featured-snippet answer: For older radiopharmaceutical kits, the main revenue risks come from any exclusivity that is tied to specific regulatory approvals or formulation/manufacturing IP, plus manufacturing continuity rather than from blockbuster-style patent expiries.

Commercial relevance of IP and regulatory status

For diagnostic radiopharmaceutical kits:

• revenue protection is often linked to:
  • approved kit composition and manufacturing process
  • regulatory exclusivity (if still applicable)
  • facility and operational barriers that reduce generic-like substitution feasibility
• even when IP is weak, manufacturing and quality system execution can be the binding constraint for entrants.

Data limitation that prevents quantified timelines

A complete exclusivity/patent expiration and Orange Book-style status map for TECHNEGAS KIT is not present in the prompt. Without that record, a quantified “when it loses exclusivity” timeline cannot be produced.

---

What is the likely financial trajectory pattern for TECHNEGAS KIT (qualitative)?

Featured-snippet answer: The trajectory typically follows a demand-driven, utilization-and-procurement cycle pattern, with revenue volatility driven by Tc-99m supply stability and hospital scheduling, and long-run growth capped by imaging modality substitution.

Base-case trajectory components

• Unit volume trend

  • grows with incremental PE and cardiopulmonary workups that adopt V/Q pathways
  • declines if clinical pathways increasingly favor CTPA

• Price and mix

  • volume-weighted net pricing can compress during contracting cycles
  • mix can shift toward higher-volume hospital networks with standardized protocols

• Operational continuity

  • consistent kit availability supports stable revenue
  • shortages or supply disruptions can cause order deferrals and lost opportunity

Scenario drivers

• CTPA pathway adoption
  • increases may reduce V/Q imaging volumes
• Radiology/nuclear medicine capacity
  • if CT capacity is constrained or if guidelines favor V/Q in certain cohorts, TECHNEGAS KIT utilization can hold
• Tc-99m generator disruptions
  • can cause short-term revenue swings

---

What commercial KPIs best explain TECHNEGAS KIT revenues for investors and licensors?

Featured-snippet answer: Track Tc-99m availability, hospital V/Q procedure volume, contract win rates, and net price versus facility contracting indices.

High-signal KPIs

• Nuclear medicine V/Q volume (procedures, not just kit units)
• Tc-99m supply indicators
  • generator production continuity
  • distributor inventory levels
  • fill-rate metrics (in shortage and normal periods)
• Net price and payer mix
  • contract pricing at IDN and GPO levels
  • reimbursement changes in facility and professional components
• Customer concentration
  • top hospital systems’ reorder behaviors
• Inventory and expiration management
  • radiopharmaceutical expiry impacts realized revenue timing

---

How does reimbursement policy shape the unit economics of TECHNEGAS KIT?

Featured-snippet answer: Hospital economics are driven by reimbursement rates for nuclear medicine ventilation and interpretation, and by how payers reimburse V/Q pathways compared with CTPA.

Mechanisms

• If payers reimburse V/Q imaging at rates that remain competitive against CTPA episode-of-care economics, utilization stays stable.
• If coverage rules expand CTPA-first strategies, the market shifts away from ventilation kits.

---

What generic entry risks exist for TECHNEGAS KIT?

Featured-snippet answer: Entry risk is constrained by manufacturing and quality system execution, radiopharmaceutical handling requirements, and protocol switching costs, but pricing pressure can rise if supply increases or if alternatives are clinically equivalent in practice.

Practical entry barriers

• specialized manufacturing approvals and release testing
• quality assurance controls for radiopharmaceutical consistency
• hospital workflow integration and physician acceptance

Without a specific regulatory and patent landscape for TECHNEGAS KIT in the prompt, a quantified paragraph IV-style or ANDA/505(b)(2) entry timeline cannot be provided.

---

Key Takeaways

• TECHNEGAS KIT demand is driven primarily by ventilation-perfusion imaging utilization, hospital protocol standardization, reimbursement economics, and Tc-99m generator supply continuity.
• Upside is limited by substitution from CT pulmonary angiography in suspected PE pathways and by payer coverage dynamics.
• The most finance-relevant volatility typically comes from supply stability (Tc-99m logistics) and hospital contracting cycles rather than from blockbuster-style exclusivity cliffs.
• A quantified financial trajectory and exclusivity/patent timeline cannot be produced from the information provided in the prompt without inventing data.

---

FAQs

1) How sensitive is TECHNEGAS KIT demand to Tc-99m shortages?

Supply continuity and generator availability drive near-term procedure scheduling and fill rates, creating revenue volatility during shortage periods.

2) Does TECHNEGAS KIT compete more on price or on protocol adherence?

Protocol adherence and workflow integration are usually the binding factors; price competition matters mainly through contracting cycles within networks.

3) What imaging pathway shifts most affect TECHNEGAS KIT revenue?

Any sustained movement toward CTPA-first PE diagnostic strategies reduces V/Q ventilation kit usage.

4) Are radiopharmaceutical “generic” entrants usually limited to cost, or constrained by production capability?

Production capability and regulatory-quality systems are often the binding constraints, not just active ingredient equivalence.

5) What KPIs should a buyer or investor monitor monthly?

V/Q procedure volume, reorder rates by IDN, fill-rate and lead-time metrics, and net pricing changes tied to facility contracting.

---

References (APA)

1. [No sources were provided in the prompt, and no TECHNEGAS KIT financial or regulatory dataset was included.]